<DOC>
	<DOCNO>NCT03009344</DOCNO>
	<brief_summary>This multicenter , single-arm , open-label , Phase 1 study ass tolerability , safety , pharmacokinetics , preliminary anti-tumor activity tazemetostat participant relapse refractory B-cell non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>A Phase 1 Study Tazemetostat Patients With Relapsed Refractory B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Participants histological diagnosis Bcell nonHodgkin 's lymphoma Participant measurable disease Participant previous therapy systemic chemotherapy and/or antibody therapy Participant progressive disease ( PD ) response ( complete response [ CR ] partial response [ PR ] ) previous systemic therapy , relapse progress previous systemic therapy Participant Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Participant life expectancy ≥3 month start study drug administration Participant adequate renal , bone marrow , liver function Participant leave ventricular ejection fraction ( LVEF ) &gt; 50 % Male female participant ≥20 year age time inform consent Participant provide write consent participate study Participant prior exposure EZH2 inhibitor Participant history presence central nerve invasion Participant allogeneic stem cell transplantation Participant medical need continue use potent moderate inhibitor CYP3A Pgp , potent moderate inducer CYP3A ( include St. John 's wort ) . Participant significant cardiovascular impairment Participant prolongation correct QT interval use Fridericia 's formula ( QTcF ) &gt; 480 millisecond ( msec ) Participant venous thrombosis pulmonary embolism within last 3 month start study drug Participant complication hepatic cirrhosis , interstitial pneumonia , pulmonary fibrosis Participant active infection require systemic therapy Women childbearing potential man impregnate potential n't agree use medically effective method contraception period inform consent clinical study 30 day later last administration study drug Woman pregnant breastfeeding Participant deem inappropriate participate study investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>relapsed refractory B-cell non-Hodgkin 's lymphoma</keyword>
	<keyword>tazemetostat</keyword>
	<keyword>Japan</keyword>
</DOC>